Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma

Neoplasma

Volumn 58, Issue 3, 2011, Pages 217-226

  Trivedi, T I ^a   Tankshali, R A ^a   Goswami, J V ^a   Shukla, S N ^a   Shah, P M ^a   Shah, N G ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Biological behavior; Immunohistochemistry; Oral squamous cell carcinoma; Prognosis; Site specific biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEEK MUCOSA; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOKING; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR VOLUME; AGED; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; PROGNOSIS; TONGUE TUMOR;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961105791     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_217     Document Type: Article

References (47)

1. NEMETH Z, VELICH N, BOGDAN S, UJPAL M, SZABO G et al. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma 2005; 52: 95-102.
2. BETTENDORF O, PIFFKO J, BANKFALVI A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004; 40: 110-119. doi:10.1016/j.oraloncology.2003.08.010
3. SEVERINO P, ALVARES AM, MICHALUART JR P, OKAMOTO OK, NUNES FD et al. Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes 2008; 1: 113. doi:10.1186/1756-0500-1-113/
4. DOBROSSY L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 2005; 24: 9-17. doi:10.1007/s10555-005-5044-4
5. TIMAR J, CSUKA O, REMENAR E, REPASSY G, KASLER M. Progression of head and neck squamous cell cancer. Cancer Metastasis Rev 2005; 24:107-127. doi:10.1007/s10555-0055051-5
6. URIST MM, O'BRIEN CJ, SOONG SJ. Squamous cell carcinoma of buccal mucosa: analysis of prognostic factors. Am J Surg 1987; 154: 411-414. doi:10.1016/0002-9610(89)90014-7 doi:10.1016/0002-9610(89)90014-7
7. MARTINEZ-CONDE R, AGUIRRE JM, BURGOS JJ, RIVERA JM. Clinicopathological factors in early squamous cell carcinoma of the tongue and floor of the mouth, in Biscay (the Basque Country, Spain). Med Oral 2001; 6: 87-94.
8. LANDIS SH, MURRAY T, BOLDEN S, WINGO PA. Cancer statistics, CA Cancer J Clin 1998; 48:6-29. doi:10.3322/canjclin.48.1.6
9. PATERSON IC, EVESON JW, PRIME SS. Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol 1996; 32:150-153. doi:10.1016/09641955(95)00065-8
10. RIDGE JA, GLISSON BS, HORWITZ EM, MN L. Cancers of the Head and Neck Region. In: Textbook of cancer management: a multidisciplinary approach. 10th edn. Melville, NY: PPR, Inc. 2007; 31-72.
11. BELBIN TJ, SCHLECHT NF, SMITH RV, ADRIEN LR, KAWACHI N et al. Site-specific molecular signature predicts aggressive disease in HNSCC. Head and Neck Pathol 2008; 2: 243-246. doi:10.1007/s12105-008-0071-4
12. SHAH NG, TRIVEDI TI, TANKSHALI RA, GOSWAMI JV, JETLI DH et al. Prognostic Significance of Molecular Markers in oral squamous cell carcinoma: A multivariate analysis. Head Neck 2009; 31: 1544-1556. doi:10.1002/hed.21126
13. BOVA RJ, QUINN DI, NANKERVIS JS COLE IE, SHERIDAN BF et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999; 5: 2810-2819.
14. GOTO H, KAWANO K, KOBAYASHI I, SAKAI H, YANAGISAWA S. Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 2002; 38: 549-556. doi:10.1016/S13688375(01)00121-X
15. LIM SC, ZHANG S, ISHII GA, ENDOH Y, KODAMA K et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 2004; 10: 166-172. doi:10.1158/1078-0432.CCR-0533-3
16. LIU CJ, CHANG KW, CHAO SY, KWAN PC, CHANG SM et al. The molecular markers for prognostic evaluation of arecaassociated buccal squamous cell carcinoma. J Oral Pathol Med 2004; 33: 327-334. doi:10.1111/j.1600-0714.2004.00092.x
17. UICC. TNM classification of malignant tumors. UICC Technical Report Series 1980; 5: 2.
18. BRODERS AC. Microscopic grading of cancer. Surgical Clinics of North America 1941; 21: 947 962.
19. VORA HH, SHAH NG, PATEL DD, TRIVEDI TI, CHIKHLIKAR PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: Multivariate analysis. J Sur Oncol 2003; 82: 34-50. doi:10.1002/jso.10183
20. VICENTE CARLOS DE J, ZAPATERO AH, FRESNO MF, LOPEZ-ARRANZ. Expression of cyclin D1 and ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance. Oral Oncol 2002; 38: 301-308. misctextdoi:10.1016/S1368-8375(01)00060-4/misctext
21. MASUDA M, HIRIKAWA N, NACKASHIMA T, KURATOMI Y, KOMIYAMA S. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer (Phila.), 1996; 78: 390-395. doi:10.1002/(SICI)1097-0142(19960801)78:3<390::AID-CNCR2>3.0.CO;2-O
22. AKERVALL JA, MICHALAIDES RJ, MINETA H, BALM A, BORG A et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer (Phila.) 1997; 79: 380-389. doi:10.1002/(SICI)10970142(19970115)79:2;380::AID-CNCR22;3.0.CO;2-W
23. MICHALAIDES RJ, VAN HEELEN NM, KRISTEL PMP, HART AAM, LOFTUS BM et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 1997; 123: 497-502.
24. HALL M, and PETERS G. Genetic alterations of cyclins, cyclindependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res 1996; 68: 65-108.
25. WEINBERG RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
26. LAM KY, NG IO, YUEN AP, KWONG DL, WEI W. Cyclin D1 expression in oral squamous cell carcinomas: clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000; 29: 167-172. doi:10.1034/j.16000714.2000.290404.x
27. XU J, GIMENEZ-CONTI IB, CUNNINGHAM JE, COLLET AM, LUNA MA et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998; 83: 204-212. doi:10.1002/(SICI)10970142(19980715)83:2<204::AID-CNCR2>3.0.CO;2-Q
28. RAJU B, MEHROTRA R, OIJORDS BAKKEN G, AI-SHARABI AK, VASSTRAND EN et al. Expression of p53, cyclin D1 and Ki-67 in pre-malignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res 2005; 25: 4699-4706.
29. COSTA A DE LL, ARAÚJO JÚNIOR RF, RAMOS CCF. Correlation between TNM classification and malignancy histological feature of oral squamous cell carcinoma. Revista Brasileira de Otorrinolaringologia 2005; 71: 181-187. misctextdoi:10.1590/S0034-72992005000200011/misctext
30. KLIJANIENKO J, BRAUD FD, RUSSO A, JANOT F, LUBOINSKI B et al. Tumor vascularization, mitotic index, histopathologic grade and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 1995; 75:1649-1656. doi:10.1002/1097-0142(19950401)75:7<1649:: AID-CNCR2820750715>3.0.CO;2-E
31. ODELL EW, JANI P, SHERRIFF M, AHLUWALIA SM, HIBBERT J et al. The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. Cancer 1994; 74: 789-794. doi:10.1002/10970142(19940801) doi:10.1002/1097-0142(19940801)74:3;789:: AID-CNCR2820740302;3.0.CO;2-A
32. BOWMEN T, GARCIA R, JOVE R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488. doi:10.1038/sj.onc.1203527
33. BROMBERG J. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-1142. doi:10.1172/JCI15617
34. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G, ZHAO Y, PESTELL RG et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. doi:10.1016/S0092-8674(00)81959-5
35. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM, TURKSON J, LEVITZKI A et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. doi:10.1016/S1074-7613(00)80011-4
36. MASUDA M, SUZUI M, YASUMATU R, NAKASHIMA T, KURATOMI Y et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 3351-3355.
37. HSIAO JR, JIN YT, TSAI ST, SHIAU AL, WU CL, SU WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003; 89: 344-349. doi:10.1038/sj.bjc.6601003
38. ] WIDSCHWENDTER A, TONKO-GEYMAYER S, WELTE T, DAXENBICHLER G, MARTH C et al. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002; 8: 3065-3074
39. CHAN KS, SANO S, KIGUCHI K, ANDERS J, KOMAZAWA N et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004; 114: 720-728.
40. PELENGARIS, S, KHAN M. EVAN G. Suppression of Myc-induced apoptosis in beta-cells exposes multiple innate oncogenic properties of Myc sufficient to trigger immediate carcinogenic progression. Cell 2002; 109: 321-334. misctextdoi:10.1016/S0092-8674(02)00738-9/misctext
41. Barre B, Vigneron A, Coqueret O. The Stat3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter. J Biol Chem 2005; 260: 15673-15681. misctextdoi:10.1074/jbc.M413203200/misctext
42. WATERS CM, LITTLEWOOD TD, HANCOCK DC, MOORE JP, EVAN GI. c-myc protein expression in untransformed fibroblasts. Oncogene 1991; 5: 797-805.
43. SHIN DM, LEE JS, LIPPMAN SM, HITTELMAN J, ROTH JA et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 519-529. doi:10.1093/jnci/88.8.519
44. BOYLE JO, HAKIM J, KOCH W, VAN DER RIET P, HRUBAN RH et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-4480.
45. LIN J, JIN X, ROTHMAN K, LIN HJ, TANG H, BURKE W. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res 2002; 62: 376-380
46. YU, H., R. JOVE. The STATs of cancer new molecular targets come of age. Nat. Rev. Cancer 2004; 4:97-105. doi:10.1038/nrc1275
47. SEPULVEDA P, ENCABO A, CARBONELL-UBEROS F, MINANA MD. BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoetic cells. Cell Death and Differentiation (2007) 14, 378-380. misctextdoi:10.1038/ /misctextsj.cdd.4402007